Loading, Please Wait...
LOS ANGELES, Sept. 21, 2018 (GLOBE NEWSWIRE) -- Advanced Bifurcation Systems (“ABS” or the “Company”), a clinical stage medical device company developing an innovative stenting platform which overcomes the limitations of current approaches for the treatment of bifurcation lesions in coronary angioplasties, today announced that the Company has been granted four additional patents, three in the U.S. and one in Europe.
Mr. Charles Laverty, Chief Executive Officer of Advanced Bifurcation Systems commented, “We have extended our broad patent portfolio to 40 patents globally and have unique claims and protection of our intellectual property in the U.S., Europe, Canada, China and Australia. We have made a concerted effort to protect our innovative technology and have a number of pending patents as well as opportunities for additional ones globally.”
About Advanced Birfurcation Systems
Advanced Bifurcation Systems (“ABS”) is a clinical stage medical device company developing an innovative stenting platform for simple treatment of all bifurcation lesions in coronary angioplasties. ABS has developed a novel technology which overcomes the limitations of current approaches while simplifying the procedure. The Company’s groundbreaking system consists of numerous differentiating features, including a unique modular independently movable dual-catheter system for provisional side-branch stenting as well as full bifurcation stenting with a proprietary crimping technology allowing for partial crimping of the main stent. For more information, go to www.advancedbifurcation.com.
Advanced Bifurcation Systems
Chief Executive Officer